Is TSHA a good stock to buy? We came across a bullish thesis on Taysha Gene Therapies, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on TSHA. Taysha Gene Therapies, Inc.’s share was trading at $5.36 as of June 9th.
Likoper/Shutterstock.com
Taysha Therapeutics (TSHA) is a clinical-stage genetic medicine company focused on developing TSHA-102 for Rett syndrome, and is viewed as a high-conviction opportunity given its regulatory progress, differentiated miRARE platform, and clear path toward late-stage approval and commercialization.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
TSHA-102 utilizes a AAV9 vector and proprietary miRARE autoregulatory mechanism designed to prevent MECP2 overexpression toxicity while enabling high-dose CNS delivery via intrathecal administration, creating biological moat in historically failure-prone gene therapy target.
Clinical evidence from the REVEAL Phase 1/2 program demonstrates a 100% responder rate in treated cohorts with durable functional gains and a clean safety profile with no treatment-related serious adverse events or dose-limiting toxicities reported across datasets as of March 2026. Near-term catalysts center on multiple Q2 2026 milestones including pivotal pediatric cohort readouts, ASPIRE trial data, and initiation of commercial-scale PPQ manufacturing, all of which support the planned BLA submission in late 2026 and potential FDA approval in 2027.
Financially, Taysha holds $319.8 million in cash, providing runway into 2028 while supporting disciplined R&D focus on TSHA-102 and reducing financing risk ahead of commercialization. At a $12.50 target price versus a $6.30 current price the thesis implies approximately 98% upside driven by re-rating toward risk-adjusted net present value as the market prices in a high-probability Rett syndrome approval pathway and multi-billion-dollar peak revenue potential.
Overall, Taysha Therapeutics represents a compelling bullish setup where differentiated biology, strong early efficacy, regulatory alignment, and a well-capitalized balance sheet converge to create a potentially transformative rerating opportunity as key 2026 catalysts unfold.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted Casgevy commercialization in sickle cell disease, gene editing leadership, and strong pipeline optionality. CRSP’s stock price has appreciated by approximately 25.65% since our coverage. BioEquity Watch shares a similar view but emphasizes TSHA-102 Rett syndrome regulatory inflection and miRARE-driven safety differentiation.
Taysha Gene Therapies, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 31 hedge fund portfolios held TSHA at the end of the first quarter which was 32 in the previous quarter. While we acknowledge the risk and potential of TSHA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TSHA and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
